The National Health Surveillance Agency (Anvisa) has prohibited the commercialization and advertising of all Golden CBD Plus and Golden CBD+ Nanotech products. The preventive measure was formalized in Resolution-RE No. 4,030, published last Monday (13), and is valid for all batches.

In a statement, Golden CBD+ informed that they "operate in total compliance with RDC 660/2022, exporting their products directly from the United States to Brazilian patients authorized by Anvisa". The company also highlighted that they "were not officially notified to provide clarifications before the publication of the measure" and that "appropriate administrative and legal actions are being taken".

According to Anvisa, the decision was motivated by evidence that the company, identified as Golden CBD Plus - USA, was selling and promoting its cannabis-derived products on a Brazilian website without any registration or authorization from the agency. Among the items listed in the resolution were oils with different appeals, such as "Sleep", "Painkiller", and "Anti Anxiety".

As per the resolution, the company does not have an Operating Authorization (AFE) from Anvisa, violating articles 2, 12, 50, and 59 of Law No. 6,360/1976. The prohibition of Golden CBD products extends to any individual, legal entity, or communication vehicle that commercializes or promotes them.

The Sechat portal's report contacted Golden CBD Plus to request a statement regarding Anvisa's measure. However, no response was received at the time of publication of this article, leaving the future of Golden CBD products in the country uncertain.

Golden CBD+ Statement - Golden CBD+ informs that they became aware of the publication of Resolution No. 4,030/2025, issued by Anvisa, which determined a precautionary measure to prohibit the commercialization and advertising of their products, based on alleged improper disclosure and sales through the website https://goldencbdplusbrasil.com.

Golden CBD+ is an American company that operates in total compliance with RDC 660/2022, exporting their products directly from the United States to Brazilian patients authorized by Anvisa, with a medical prescription and required legal documentation; The mentioned website is maintained by the American company, hosted abroad, and uses the term "Brazil" only to facilitate access to information for Brazilian patients, with content in Portuguese, without any sales made through a national website;

The company does not make sales other than through importation to Brazil, only selling to end consumers, following Brazilian regulations, with deliveries exclusively made in the context of direct and exclusive importation, as provided by RDC 660/2022.

The company was also not officially notified to provide clarifications before the publication of the measure. We reaffirm our deep respect for Anvisa and Brazilian health authorities, and the company has already submitted a formal request for clarifications on the measure, in order to understand the grounds and, if necessary, make any adjustments.

Appropriate administrative and legal actions are being taken, including before the competent authorities, focusing on dialogue, transparency, and compliance with the law. Golden CBD+ is a serious company, internationally recognized for offering products of the highest quality, with strict standards of safety, efficacy, and purity.

We remain committed to health, science, and compliance with regulatory standards. Golden CBD+ Team